Tranexamic acid use in critically ill children with hemorrhage: a single-center retrospective descriptive study
This single-center retrospective study describes the usage patterns, transfusion requirements, and clinical outcomes of 44 critically ill children receiving tranexamic acid for hemorrhage in a PICU, noting a low rate of thrombotic events but emphasizing the need for prospective research to establish efficacy and safety due to the lack of a control group.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a child suffers a severe injury or becomes critically ill, the body's natural response to stop bleeding can sometimes go into overdrive, breaking down clots too quickly and leading to dangerous, uncontrolled blood loss. To help the body regain control, doctors often use a medication called tranexamic acid. This drug works by acting like a brake on the body's clot-dissolving system, allowing clots to form and stay intact long enough to heal the wound. While this treatment is well-established for adults with major trauma, its use in children is less clear. Children are not simply small adults; their bodies react differently to injury and illness, and the reasons they bleed can range from car accidents to complex internal diseases. Because the evidence for how best to use this drug in pediatric intensive care units is limited, doctors often rely on their own judgment, creating a patchwork of practices that need careful observation to understand.
In a recent study conducted at a single hospital in Turkey, researchers set out to describe exactly how tranexamic acid is being used in a real-world pediatric intensive care unit. They looked back at the medical records of 44 children who received the drug for bleeding between 2020 and 2023. The group of children was diverse, with an average age of about six years, and included both boys and girls. Roughly half of these children had been admitted due to trauma, such as car accidents or falls, while the others were there for non-traumatic reasons like severe infections or complications from other illnesses. The most common place where these children were bleeding was inside the skull, followed by the lungs and the digestive tract.
The researchers found that the timing and duration of the treatment varied significantly from patient to patient. On average, the medication was started about six hours after the bleeding began, which is later than the ideal window often recommended for trauma patients. The drug was typically given for nearly four days, a much longer course than the short, single-dose regimens often seen in adult trauma care. The doctors in the study decided when to start and stop the drug based on their own clinical judgment rather than a strict, uniform protocol. In most cases, the medical team reported that the bleeding seemed to stop or slow down after the treatment began, though this observation was based on their notes rather than a standardized test.
Despite the high severity of the children's conditions—many required machines to help them breathe or support their heart function—the study did not find a clear link between how quickly the drug was given and whether the child survived. The children who died had started treatment at roughly the same time as those who survived. This suggests that in these complex cases, the timing of the drug might not be the deciding factor for survival, or that the severity of the underlying illness was simply too great for the medication to overcome. The study also tracked safety, looking for serious side effects like blood clots or seizures. Only one child developed a blood clot in a leg vein, and no seizures were recorded. However, the researchers were careful to note that because they did not actively screen every child for hidden clots, these numbers might not tell the whole story about safety.
The most striking pattern the team observed was in the need for blood transfusions. Before the drug was given, a large number of children required transfusions of red blood cells, plasma, or platelets. As time passed after the treatment started, the number of children needing these blood products dropped. While this decline is encouraging, the researchers emphasized that they could not prove the drug caused it. The bleeding might have stopped on its own, or the children might have received other life-saving procedures at the same time. Without a control group of similar children who did not receive the drug, it is impossible to say for certain that the medication was responsible for the improvement.
Ultimately, this study serves as a detailed map of current practices rather than a final verdict on the drug's effectiveness. It shows that doctors are using tranexamic acid for a wide variety of bleeding problems in critically ill children, often for longer periods and with different timing than in adult trauma cases. The findings suggest that while the treatment appears to be used without causing immediate, widespread harm in this specific group, the evidence is not yet strong enough to confirm that it saves lives or prevents complications in children. The authors conclude that to truly understand how to use this drug safely and effectively for children, larger studies involving many hospitals are needed to compare treated patients with those who are not, and to establish clear rules for who should receive it, when, and for how long.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.